The mechanism of BRCA1 tumor suppression in human breast and ovarian cells is the focus of intense investigation. In this report, full length BRCA1 (230 kDa) introduced into cells with CMV promoter constructs was nuclear when transgene expression was low whereas high expression resulted in cytoplasmic accumulation, aberrant nuclear and cell morphology. A nuclear localization signal (NLS) was mapped to BRCA1 amino acid positions 262 ± 570. We describe a splice variant, BRCA1-D11b, missing the majority of exon 11 including the NLS. Exogenous BRCA1-D11b (110 kDa) was cytoplasmic and, unlike the full-length protein, overexpression of the protein encoded by the variant did not appear to be toxic. RNA probe titrations and RT ± PCR demonstrated that BRCA1 and D11b transcripts are coexpressed in a wide variety of cells and tissues. Interestingly, BRCA1-D11b message was greatly reduced or absent in several breast and ovarian tumor lines relative to exon 11 transcripts and a D9,10 splice variant. Taken together our results suggest that fulllength BRCA1 and BRCA1-D11b may have distinct roles in cell growth regulation and tumorigenesis.
Introduction
Inherited mutations in the human BRCA1 gene predispose individuals to early onset breast and ovarian cancer Futreal et al., 1994; Castilla et al., 1994; Friedman et al., 1994; Struewing et al., 1995; Shattuck Eidens et al., 1995; Merajver et al., 1995b) . Elaboration of the disease in these individuals is frequently associated with loss of the wild type allele Cornelis et al., 1995; Merajver et al., 1995a) thus, genetically BRCA1 behaves like a tumor suppressor gene. BRCA1 consists of 22 functional exons which together encode a protein of 1863 amino acids with a predicted size of 206 kDa . The presence of a ring-®nger motif (Bienstock and Darden, 1996) that may function in DNA binding, putative nuclear localization signals (NLS) and an acidic C-terminal domain has generated speculation that BRCA1 may act as transcriptional regulator. It has also been proposed that BRCA1 is a granin-like protein that functions as a secreted growth inhibitory protein (Jensen et al., 1996a; Holt et al., 1996) .
Several recent molecular studies generally support the function of BRCA1 inferred from the human genetic analysis. First, BRCA1 expression has been shown to be ®ve to 15-fold lower in invasive cancer cells than in normal breast tissue or pre-invasive ductal carcinoma in situ (Thompson et al., 1995) . Second, anti-sense oligonucleotide treatment accelerates the growth of primary mammary epithelial cell cultures and MCF-7 cancer cells (Rao et al., 1996) . Third, transfection of wild type BRCA1 inhibits the growth of breast and ovarian cancer cells, while lung and colon cancer cells are essentially unaected (Holt et al., 1996) .
The phenotype of homozygous mice carrying targeted Brca1 mutations in exon 5,6 (Hakem et al., 1996) indicates that Brca1 has an essential function in general cell proliferation in addition to its role as a tumor suppressor in the breast and ovary. Exon 5, 6 knockout mice die in utero before gastrulation at around day 5.5 ± 6.5 with poorly developed embryonic and extra-embryonic tissues. Moreover, homozygous mutant embryonic stem (ES) cells do not appear viable. The concept that Brca1 is necessary for cell proliferation is supported by its pattern of expression in the embryo and adult. In the mouse embryo, the highest levels of Brca1 expression is detected in rapidly dividing cells undergoing dierentiation in a broad range of tissues (Marquis et al., 1995; Lane et al., 1995) . In the adult human, the highest transcript concentrations occur in the thymus and testes . Moderate expression has been observed in the breast, ovary, uterus, spleen, liver and lymph nodes with lower expression reported in a variety of other organs and tissues. BRCA1 message accumulation can be regulated by estrogen and progesterone (Gudas et al., 1995; Marquis et al., 1995) and it is induced in the mammary gland during puberty and pregnancy (Marquis et al., 1995) .
In contrast to the exon 5,6 mutant, exon 11 knockout embryos generated by Gowen et al. (1996) survive well past gastrulation and homozygous Brca1 11 mutant ES cells are viable. These exon 11 mice appear to die of neurogenic defects around day 9.5 ± 10.5 of development. This result implies that Brca1 is required for the dierentiation of speci®c cell types in late embryogenesis. Recently, a second exon 11 knockout has been described in which Brca1 amino acids 300 ± 361 were deleted (Liu et al., 1996) . Unlike the Gowen knockout, embryos homozygous for the Brca1 300 ± 361 deletion arrest at an early stage of development (E5.5 ± 6.5). The cDNA clones described in the original report presenting the BRCA1 sequence implied that several alternatively spliced transcripts are expressed. Little is known about the structure and function of the proteins encoded by these transcripts since most attention has been focused on the full length protein.
Alternative splicing could generate several dierent Brca1 mRNA in the exon 11 knockouts in which the normal reading frame is maintained without exon 11. The messages could not have been produced in the Brca1 5, 6 mutants. The role of alternative Brca1 proteins, if any, in the phenotypic dierences observed between exon 5,6 and exon 11 mutant embryos is not yet clear. However, the developmental importance of exon 11 minus BRCA1 transcripts is supported in the human by the existence of a breast cancer patient having a homozygous nonsense mutation in Brca1 exon 11 (Boyd et al., 1995) .
Recently, the severity of breast cancers classi®ed according to proliferative index was compared to the positions of mutations in BRCA1. A signi®cant correlation was found between truncations at the N and C termini of BRCA1 and the most highly proliferating cancers (Sobol et al., 1996) . Interestingly, the manifestation of nonsense mutations in exon 11 were less serious than truncations near the end of the protein. These ®ndings support tumor suppressive roles for alternatively spliced BRCA1 variants containing the N and C terminal exons. Chen et al. (1995 Chen et al. ( , 1996 have published data demonstrating that BRCA1 is a nuclear protein in normal cells, whereas the protein was aberrantly located in the cytoplasm in breast and ovarian cancer cells. In contrast, Scully et al. (1996) have found that BRCA1 is exclusively nuclear regardless of cell type. Both groups agree that the protein is nuclear in normal cells. The apparent molecular weight reported for the nuclear (220 kDa) and secreted (190 kDa) forms of BRCA1 in SDS ± PAGE are signi®cantly dierent. However, the entire BRCA1 protein sequence is claimed to be present in both forms based on comparisons with recombinant protein produced in vitro or in vivo. We have shown that the analysis of BRCA1 subcellular localization has been complicated by the fact that a crucial antibody (C-20, Santa Cruz) crossreacts with the epidermal growth factor receptor (EGFR) and Her2 (Wilson et al., 1996) which are frequently overexpressed in human breast and ovarian cancers and malignant cell lines (Lewis et al., 1993; Earp et al., 1995) . The level of EGFR expression in the MDA-MB-468 cells used to characterize BRCA1 secretion is particularly high (Wilson et al., 1996; Filmus et al., 1985) . Thus, the issue of BRCA1 subcellular localization needs to be examined further.
In this report we attempt to more fully characterize the BRCA1 proteins and address some of the controversial issues in the literature regarding this important molecule (Wilson et al., 1996; Chen et al., 1996; Scully et al., 1996; Koonin et al., 1996; Diamandis, 1996; Bradley and Sharan, 1996; Jensen et al., 1996b) . We describe the isolation of an alternatively spliced BRCA1 message in which the majority of exon 11 (905 ± 4215) has been deleted. This transcript, referred to as BRCA1-D11b is underrepresented in some breast and ovarian cancer cell lines relative to exon 11 containing transcripts. We analyse subcellular localization using CMV promoter vectors that express proteins with or without epitope tags. These analyses demonstrate that a functional nuclear localization signal (NLS) is encoded in exon 11b and that BRCA1-D11b which lacks this sequence is constitutively cytoplasmic. Transfection of BRCA1, but not BRCA1-D11b transgenes frequently appeared toxic to cells. The toxicity seen with full length BRCA1 expression was associated with accumulation of the protein in the cytoplasm and nuclear fragmentation.
Results

Isolation of BRCA1 clones
In an attempt to clone the full length BRCA1 cDNA for the purpose of protein characterization studies, primers were designed to PCR amplify the entire 5.7 kb coding sequence of BRCA1 from breast tumor or human colonic epithelial cDNA. The 5' primer in these reactions corresponded to nucleotides 123 ± 146 of the BRCA1 sequence and the 3' primer contained antisense nucleotides 5674 ± 5708. After several attempts, a product containing the full length coding region was ampli®ed, cloned, sequenced and found to be identical to published sequence except for the changes described in Materials and methods. However, a 2.2 kb DNA most frequently ampli®ed was also sequenced and found to encode an open reading frame consisting of BRCA1 amino acids 2 ± 262 joined to amino acids 1366 ± 1863 (Figure 1a ). This BRCA1 variant, which is missing exon 4 and most of exon 11 (positions 908 to 4215 (11b)), will be referred to as BRCA1-D11b. The portion of exon 11 included in BRCA1-D11b has been named exon 11a. The BRCA1-D11b protein sequence is dierent from the BRCA1 GenBank sequence at two positions highlighted by solid dots. The ®rst change is a three nucleotide deletion resulting in the loss of an alanine at position 1453. This alanine is also missing in the published sequence . The second dierence is a serine to glycine substitution at amino acid position 1612. The glutamine, position 1456, at the exon 13 ± 14 junction in the published sequence is also missing in BRCA1-D11b and in the GenBank sequence. The minor sequence variants in BRCA1-D11b described above were observed in several independently isolated clones and thus are probably sequence polymorphisms. The BRCA1-D11b clone does contain three substitutions that are either cloning artifacts or rare, unpublished sequence polymorphisms (open circles). We do not believe that these changes have aected the experiments described in this report since the ®rst two are conservative changes and the third is in a region of the protein not conserved between the mouse and human genes.
BRCA1-D11b is generated by an alternative splicing event using a donor site present in exon 11 at nucleotide positions 905 ± 909 (Figure 1b ). This donor site is fused to the exon 12 splice acceptor as illustrated in Figure 1c . The glycine generated by the exon 11 ± 12 junction ( Figure 1d ) is maintained in the exon 11a ± 12 splice, thereby preserving the normal reading frame of exons 12 ± 24. Exon 11b encodes two putative nuclear localization elements previously noted in BRCA1 (Chen et al., 1995) . Thus, one of the most signi®cant functional consequences of the exon 11b alternative splice is the potential generation of an obligate cytoplasmic BRCA1 variant. It should be noted that a splice variant missing exons 9 ± 11 was described in the initial publication of the BRCA1 sequence .
Measurement of BRCA1 transcript prevalence
The prevalence of BRCA1 and BRCA1-D11b and transcripts in the HBL100 breast cell line was determined by RNA probe titration. The probe used for this measurement was transcribed from a DNA fragment ampli®ed from the BRCA1-D11b plasmid with a forward primer starting at position 826 of exon 10, and a reverse primer which included the T7 promoter, starting at position 1145 of exon 13. As shown in Figure 2a , the length of the probe protected by the BRCA1-D11b mRNA is 337 nt. Transcripts containing exon 11b were expected to generate Structure of BRCA1-D11b and BRCA1 exon 11b hybrids. The 32 P-labeled antisense RNA probe used for the protection analysis contained BRCA1-D11b sequences spanning the exon 11a ± 12 splice junction as described in Materials and methods. The probe fragments protected by BRCA1-D11b and BRCA1 exon 11b transcripts are represented schematically as gray bars. BRCA1-D11b protects a continuous 337 nt fragment (top black bar) whereas in hybrids containing exon 11b, the probe is RNase sensitive at the 11a ± 12 splice junction generating 77 nt and 260 nt products. (b) RNase protection assay. The RNase resistant products were separated on a denaturing polyacrylamide gel and the position of protected fragments was visualized with a Molecular Dynamics Phosphorimager. A small amount of intact, non-digested GAPDH probe or BRCA1 probe was loaded in lanes 1 and 3 respectively to verify probe integrity. Lane 2 contained the GAPDH product protected by 20 mg of HBL100 total RNA. A control reaction consisting of the BRCA1 probe and 20 mg total yeast RNA is shown in lane 4. The titration of BRCA1 probe with decreasing quantities (100, 80, 60, 40, 20 mg) of HBL100 total RNA was analysed in lanes 5 ± 9. (c) Regression analysis of transcript titration. The signal obtained for the 337 nt (open circles) and 260 nt (closed circles) bands was plotted against the amount (mg) of HBL100 total RNA. The lines drawn through the data were determined by linear regression excluding the 60 mg data point where half the sample was lost fragments of 77 and 260 nt since the 3310 nt sequence separating exon 11a and exon 12 is susceptible to internal cleavage. Increasing amounts (20 ± 100 mg) of HBL100 total RNA were incubated with a ®xed amount of 32 P-label probe and the products obtained after treatment with RNase A and T1 were displayed on a denaturing acrylamide gel (Figure 2b ). Protected fragments of about 260 and 337 nt were observed in similar proportions (lanes 5 ± 9). The 77 nt fragment was not retained on the gel. No bands were observed in the control reaction (lane 4) which contained yeast RNA, indicating that the signal was speci®c for BRCA1 transcripts. The experiment also included a control assay for the abundant GAPDH message. The GAPDH signal obtained with 20 mg total RNA (lane 2) was ®ve to 10-fold greater than the combined amount of resistant BRCA1 probe observed with an equal RNA quantity (lane 9). BRCA1 transcript concentrations were derived from the slope of the regression lines drawn through the titration data for the 260 or 337 nt bands (Figure 2c ). Using the probe speci®c activity to convert the slopes to mass units, it was determined that HBL100 RNA protected 24 fg BRCA1 and 19 fg of exon BRCA1-D11b per mg of total RNA. These estimates were translated into transcript concentrations of 31 copies per cell of BRCA1 message and 19 copies per cell of BRCA1-D11b using 25 pg as the amount of total RNA per cell (Lee and Costlow, 1987) . These BRCA1 prevalence values fall in the range assigned to mRNA of low to moderate abudance (Galau et al., 1977) .
RT ± PCR expression analysis in cell lines
The expression levels of BRCA1, BRCA1-D11b and two other alternatively spliced transcripts in total RNA isolated from breast and ovarian cell lines were examined using RT ± PCR. RNA from sublines, generated by stable retroviral transfection of the Her2 receptor, was included to investigate whether or not the more aggressive growth characteristics associated with Her2 overexpression were correlated with changes in BRCA1 transcript levels. The positions of the forward and reverse primers, the size of the observed products and the exons represented in these assays are summarized in Table 1 where the coordinates refer to the nucleotide position in the full-length BRCA1. Each RNA sample was tested at four amounts starting at 250 ng followed by three, ®vefold serial dilutions. The rTth polymerase which combines high temperature reverse transcriptase and DNA polymerase activity was used for PCR ampli®cation to avoid variation introduced by oligo (dT) or random cDNA priming and a Biomek 2000 was used to robotically assemble RNA dilutions and PCR reactions to minimize pipetting errors. The RNA samples to be compared were ampli®ed simultaneously and the products were analysed on the same gel where precautions were taken to insure uniform ethidium bromide staining. Under these conditions, dierences in RNA concentration of 10 ± 25-fold or greater are reproducibly detected. The signals obtained with a particular RNA sample with dierent primer pairs cannot be compared since the variance in ampli®cation eciency is geometrically ampli®ed.
Primer pair (852/4431) was designed to amplify a 271 bp sequence that includes the exon 11a ± 12 splice junction of BRCA1-D11b. As shown in Figure 3a , a prominent PCR product (®lled arrow) at the expected position was detected with HBL100 RNA. The sequence of this ampli®cation product (D11b) was identical to the expected BRCA1-D11b region, thus con®rming that the 11a ± 12 splice occurs in vivo as indicated by the ribonuclease probe protection experiment. The longer product representing full length exon 11 (3387 bp) was not observed due to the short PCR extension time. The amount of the D11b ampli®cation product appeared to be greatly reduced or absent in MCF-7, MDA-231, BT20 breast tumor cells and the CaOV-3 ovarian tumor line. In contrast, a signal was detected at the third or fourth RNA dilution in these cell lines with primer pairs (2631/2923) that amplify exon 11b 2631 ± 2923 . The level of BRCA1 transcripts was not dramatically in¯uenced by Her2 overexpression. To determine if other BRCA1 splice variants are dierentially regulated, the cell line panel was assayed with a primer pair (621/947) designed to detect transcripts missing exons 9 and/or 10. The two products predicted for transcripts containing exons 9,10 (327 bp) and the BRCA1-D9, 10 variant (207 bp) were obtained in all cell lines in approximately equal proportions. Transcripts missing exons 9 or 10 alone were not detected. Taken together these results indicate that the 11a ± 12 alternative splice is dierentially regulated in the tumor cell lines while joining of exons 8 and 11 is not. 
RT ± PCR expression analysis of tumors and normal tissues
The 2631/2923 and 852/4431 primer pairs were used to assay the expression of Brca1 (exon 11b 2631 ± 2923 ) transcripts and BRCA1-D11b in a large panel of RNA samples. The results of this survey are summarized in Table 2 . The ampli®cation patterns of 11b 2631 ± 2923 and D11b were essentially the same in a variety of adult and fetal tissues and in RNA isolated from ovarian, colon, and lung tumors. The level of both transcripts was consistently higher in colon and lung tumors (T) when compared to the normal (N) tissue controls which were acquired from the same patient. Similarly, the amount of product obtained with fetal organs, where the proportion of dividing cells is relatively high, was greater than in the corresponding adult organ. As shown in Figure 3b , the 11b 2631 ± 2923 ampli®cation product was readily detected in 9/10 tumor and 10/10 normal samples at similar levels. Conversely, ampli®cation of the D11b product was greatly reduced in 7/10 breast tumor samples. Reduced expression was not limited to tumors since the D11b product was low or absent in 5/10 of the normal breast RNA samples. It is not yet clear whether the dierential ampli®cation of the D11b product in these experiments re¯ects tumor-speci®c splicing defects or tissue-speci®c splicing combined with variable representation of ductal epithelium, adipose and connective tissue in normal and tumor samples. Normal fetal and adult tissue samples were also assayed with the primer pair designed to evaluate exons 9,10 and a separate primer pair (210/413) that detects dierential splicing of exons 4 and 5 (data not shown). As observed with the cell lines, exon 9,10 and D9,10 transcripts were equally represented in all normal tissues. No evidence of transcripts containing exon 4 was obtained. The expression pattern of exon 5 containing transcripts was essentially identical to that of exon 11b 2631 ± 2923 whereas the ampli®cation product with the size expected for D5 transcripts was barely detectable in normal adult and fetal tissues. These results verify the initial suggestion based on cDNA cloning that alternative splicing generates a number of primary sequence variants of BRCA1 . Additional analyses will be necessary to evaluate the full diversity of BRCA1 transcripts.
Localization of BRCA1 and BRCA1-D11b proteins in situ
The subcellular localization of BRCA1 and BRCA1-D11b proteins transiently expressed in 293-EBNA and Cos-7 cells was examined by immuno¯uorescent staining in situ. BRCA1 proteins were expressed from CMV promoter plasmids that were modi®ed to include a 5' UTR derived from the human GAPDH mRNA The representation of BRCA1 exons 9 ± 11 was analysed by RT ± PCR in total RNA isolated from the various cell lines indicated using a semi-quantitative RT ± PCR protocol described in Materials and methods. The sux Her2 in the cell line name denotes sublines that overexpress a transfected Her2 cDNA and the sux con indicates the control or parental line. Each RNA source was assayed at four amounts (250, 50, 10 and 2 ng). The sequence of the primer pairs, the exon representation and length of the observed ampli®cation products are summarized in Table 1 . The 852/4431 primer pair was used to assay the exon 11a ± 12 splice junction in the RT ± PCR series denoted as D11b. The 2631/2923 primers were used to monitor exon 11b (panel 11b 2631 ± 2923 ), and primers 621/947 (panel 9,10/D9,10) ampli®ed sequences derived from transcripts containing exons 9,10 or splice variants in which these exons were removed. The ®lled arrows mask the location of the expected ampli®cation products. The open arrows mark primer dimer or unincorporated primer. (b) Expression of BRCA1-D11b in breast tumor and normal breast RNA. RT ± PCR analyses were performed as described in (a). See Table 1 for a description of the primers used to detect BRCA1-D11b transcripts (panel D11b) and exon 11b (panel 11b 2631 ± 2923 ) and two copies of a myc epitope detectable with a well de®ned monoclonal antibody. To control for the possibility that the epitope tag in¯uenced localization, the proteins were tagged at either the N or C terminus and overexpressed non-tagged BRCA1 proteins were analysed using an antibody raised against the ®rst 355 amino acids of BRCA1. The diuse nuclear staining observed in cells transfected with full length BRCA1 plasmids is shown in Figure 4a ± h. The same results were obtained with N-terminally (Figure 4a , b, e), Cterminally (Figure 4c , d, f) myc-tagged proteins and non-tagged BRCA1 (Figure 4g, h) . The propidium iodide (PI) counter stain con®rmed the identity of nuclei in 293-EBNA cells (Figure 4b, d ). Nuclear localization was more easily recognized in the large Cos-7 cells where BRCA1 was characteristically absent from nucleoli (Figure 4f, g ). BRCA1 was not exclusively targeted to nuclei. Examples of cells exhibiting both cytoplasmic and nuclear staining (Figure 4i , j) or primarily cytoplasmic staining (Figure 4k , l) were also observed. BRCA1 did not appear to be localized in the ER-golgi and it was speci®cally absent from many vesicles. As higher levels of¯uorescent protein accumulated, it appeared to be concentrated in broad peri-nuclear bands and the cells often contained more than one nucleus and nuclei that Figure 4 Full length BRCA1 displays a complex localization pattern that often coincides with aberrant cell morphology. The BRCA1 protein was overexpressed in 293-EBNA (a ± d) or Cos-7 cells (e ± t) by transient transfection of CMV promoter constructs. After 30 ± 60 h the cells were ®xed in methanol/acetone and stained with a myc monoclonal antibody or a polyclonal rabbit antiserum (B112) raised against residues 2 ± 355 of BRCA1. The cells were incubated with FITC conjugated secondary antibodies and in some cases stained brie¯y with propidium iodide (PI) to visualize nuclei. BRCA1 was produced with a myc epitope tag at the N terminus (a, b, e, k ± m, and g ± t) or C-terminus (c, d and f) of the protein or in a non-epitope tagged form (g, h, i, j, n, o and p).
Composite images (b, d, r and t) of propidium iodide staining and the FITC labeled BRCA1 proteins in a, c, q and s were included to con®rm the location and morphology of nuclei. The arrow in (t) points to a normal rounded nucleus from a non transfected cell and the arrow in (r) points to a nuclear fragment surrounded by FITC labeled cytoplasm. The confocal images in (a ± d, j, l) and (q ± t) were digitally captured on an ACAS microscope with a 1006 oil immersion lens. The images in e ± h, i, k and m ± p were obtained with a 406 objective on a Nikon Microphot-FXA microscope equipped with a color video printer. The relative scale of (q ± t) was changed to accommodate more cells in each panel
were swollen compared to those of normal cells (Figure 4m ± t). As the intensity of peri-nuclear signal increased, nuclei were more fragmented, the amount of DNA detected with PI stain was decreased and the plasma membrane appeared to curl and shrink. Finally, the cells became round and non-adherent with a small nuclear residue stained by PI (Figure 4r, t) .
To investigate the possibility that full length BRCA1 and BRCA1-D11b are targeted to dierent subcellular compartments, myc-tagged or non-tagged BRCA1-D11b proteins were introduced by transient transfection into 293-EBNA and Cos-7 cells. In every cell examined, the myc-tagged protein (Figure 5a ) or nontagged protein (Figure 5b ) was restricted to the cytoplasm. In Cos-7 cells, where the cytoplasm is relatively large and¯at, BRCA1-D11b myc staining was uniformly dispersed throughout the cytoplasm however, the signal appeared to be excluded from many cytoplasmic vesicles as well as the nucleus (Figure 5c ). No evidence of endoplasmic reticulum or golgi staining was obtained. To verify our interpretation of nuclear and cytoplasmic staining, the myc-tag was used to examine the subcellular localization of a bona ®de transcription factor called SpP3A2 (Calzone et al., 1991) , and a SpP3A2 mutant in which the seven amino acids de®ning the NLS had been deleted. As expected, the FITC staining of wild type SpP3A2 was coincident with the PI stain (Figure 5k ). In contrast, the SpP3A2 NLS-mutant protein was exclusively located in the cytoplasmic compartment and uniformly distributed in a manner similar to that observed for BRCA1-D11b (Figure 5l ). The lack of FITC staining in the many presumptive non-transfected cells in each panel of Figure 5 indicates that the endogenous myc protein was not detected under the conditions used to analyse BRCA1 and SpP3A2.
Cells transiently transfected with full length BRCA1 and BRCA1-D11b behaved dierently in a number of respects. Firstly, a large percentage of cells expressed the exogenous D11b protein (40 ± 50%) indicating that the transfection eciency achieved in these experiments was high. However, cells containing easily detectable levels of full length BRCA1 staining were relatively rare (1 ± 2%), and their frequency was not increased in drug selected transformants. Secondly, BRCA1-D11b was exclusively cytoplasmic. In contrast, the image of full length BRCA1 subcellular localization was more complicated, ranging from predominantly nuclear to mostly cytoplasmic. Third, both 293-EBNA and Cos-7 cells tolerated high levels of BRCA1-D11b whereas high levels of the full length protein were correlated with aberrant nuclear and cell morphology and cell killing. Although transfection with lipofectamine induced a signi®cant amount of cell killing that was visible within 24 h after removal of the reagent, we consistently observed three to ®vefold more non-adherent dead cells in cultures transfected with BRCA1 constructs compared to BRCA1-D11b or vector DNA alone. These observations support the indication that overexpression of BRCA1 may be toxic to cells.
Deletion mapping of the BRCA1 NLS
The fact that BRCA1-D11b was constitutively cytoplasmic suggested that the BRCA1 NLS was encoded in exon 11b. This hypothesis was tested with a series of myc-tagged deletion mutants illustrated schematically in Figure 7 where BRCA1 and BRCA1-D11b are also represented. The hatched gray box spanning exons 2 ± 5 highlights the cysteine-rich ring ®nger motif, the two black bars in exon 11 mark the location of two putative NLS and the gray bars identify the granin motif (G) or an epitope (E) shared with the epidermal growth factor receptor (EGFR) and Her2 (Wilson et al., 1996) . It should be noted that several clones depicted in Figure 7 contain amino acids substitutions relative to the GenBank sequence that represent either sequence polymorphisms or PCR ampli®cation errors as discussed in detail in Materials and methods. None of the changes aect positions identi®ed as human BRCA1 mutations and the results obtained for the full length constructs were veri®ed with independently isolated cDNA sequences containing non-overlapping changes.
The proteins produced by the BRCA1 (1 ± 222), (1 ± 262) and (1366 ± 1863) deletion mutants were restricted to the cytoplasm (Figure 5g i, j) while the partial proteins (89 ± 679, 1 ± 570, 223 ± 1365, 263 ± 1365) that include part or all of exon 11, were eciently transported to the nucleus (Figure 5d , e, f, h). These observations are consistent with the results obtained for the BRCA1-D11b variant and demonstrate that at least one NLS is located in a 208 amino acid sequence between residues 263 ± 570 of exon 11b. This region contains a candidate NLS having the sequence KLKRKRRP (Chen et al., 1995) .
Expression of BRCA1 proteins
To con®rm that intact proteins of the predicted size were produced in the transient transfection experiments, myc-tagged BRCA1, BRCA1-D11b and the deletion series were transfected into 293-EBNA cells and protein levels were assayed in immunoblots with the myc antibody. The bands representing monomeric, exogenous myc-tagged proteins in Figure 6a are indicated by ®lled triangles. It should be noted that, except for BRCA1 (1 ± 222) and (1 ± 262), the apparent molecular weight of the myc-tagged proteins was consistently 20 ± 25 kDa greater than the size predicted from the BRCA1 protein sequences. Open triangles mark the positions of BRCA1 (1 ± 222) and (1 ± 263) protein dimers. The amount of protein dimers was increased in samples boiled in SDS without reducing agent (data not shown). Assuming that the detection eciency of the myc-epitope was similar for all the fusion proteins, it is clear that protein expression varied considerably depending on the region of BRCA1 encoded in the construct. The highest expression was obtained with plasmids that did not contain sequences of exon 11b. To detect a signal for the BRCA1 (223 ± 1365) and (263 ± 1365) fusion proteins, it was necessary to increase the relative amount of transfected plasmid, protein extract loaded on the gel, and exposure time by a combined factor of 20-to 30-fold. Since all constructs programmed the synthesis of similar amounts of protein in reticulocyte extracts (data not shown), transcripts containing exon 11 sequences do not seem to be translated with reduced eciency.
While transiently transfected 293-EBNA cells consistently produced large quantities of BRCA1- Figure 5 Cytoplasmic localization of BRCA1-D11b and mapping of a NLS in exon 11. BRCA1 constructs with and without Nterminal myc tags were transfected into 293-EBNA and Cos-7 cells which were ®xed and stained as described in Materials and methods and in Figure 4 . Myc-tagged constructs encoding the wild type transcription factor SpP3A2 and a nuclear localization mutant SpP3A2 D52-58 were also included as controls for nuclear and cytoplasmic staining. Digital images were captured from two dierent channels of an ACAS confocal microscope using a 1006 oil immersion lens. D11b protein whether myc-tagged or not, the level of full-length protein achieved in parallel cultures was relatively low. Myc-tagged BRCA1 was detected in 293-EBNA cells only in concentrated nuclear pellets (Figure 6b ; lane 1 solid arrow). An increased signal was observed for a myc-tagged protein truncated at position 1667 (BRCA1 (1 ± 1667); Figure 6b ; lane 2 hollow arrow), so it is possible that the C-terminal is responsible at least in part, for the limited accumulation of full length protein. The signal was not greatly increased using BRCA1 constructs containing three or four N-terminal copies of a hemaglutinin (HA) epitope (data not shown). For reasons that are not yet clear, Cos-7 cells expressed signi®cantly more myctagged and non-tagged BRCA1 (Figure 6b; lanes 4, 8) although expression was still low compared to BRCA1-D11b transfected cells. MDA-MB-468 total proteins were included in the blot probed with the BRCA1 C-20 antibody to illustrate the size dierence between the 190 kDa band, which we have shown is EGFR (Wilson et al., 1996) , (lane 6) and BRCA1. The molecular weight predicted for the 1863 amino acid BRCA1 protein from the cDNA sequence is 206 kDa. The apparent size of the protein in 6% SDS ± PAGE minus the mass contributed by the epitope tags when present, was approximately 230 kDa.
Cell fractionation analysis of BRCA1 and BRCA1-D11b
The subcellular localization of the BRCA1 and BRCA1-D11b proteins was also analysed by cell fractionation and The full length BRCA1 and BRCA1-D11b proteins in (b) and (c) were separated on 6% or 8% SDS ± PAGE gels respectively immunoblotting. Plasmids encoding myc-tagged and non-tagged BRCA1-D11b were transfected into 293-EBNA cells and after 36 h, nuclear and cytoplasmic extracts were prepared. Immunoblots of these proteins were probed with the BRCA1 antibody I-20 (Figure 6c ). Cells transfected with a non-tagged BRCA1-D11b plasmid overexpressed a 110 kDa protein although the predicted molecular weight is 85.7 kDa. The level of the exogenous D11b protein (lanes 3 ± 6) greatly exceeded the amount of endogenous protein produced by 293-EBNA cells (lanes 1 ± 2) . A slightly larger protein was produced in cells transfected with myc-tagged BRCA1-D11b due to the additional mass added by the epitope. For reasons which are not yet clear the level of BRCA1-D11b in the nuclear fraction was higher than expected given the cytoplasmic immunostaining observed in situ. Chemiluminescent signals are dicult to quantify rigorously, however, data from a large number of experiments showed that the D11b signal was approximately equally distributed between nuclear and cytoplasmic fractions. Similar results were obtained using a variety of detergent buers and lysis protocols as discussed in Materials and methods, and with transfected Cos-7 cells. One possibility is that the BRCA1-D11b protein is associated with detergent resistant cytoskeletal structures that were not separated from nuclei. We feel that the images of exclusive cytoplasmic localization obtained in situ (Figure 5a ± c) are the most accurate representation of BRCA1-D11b subcellular localization since this analysis was performed in non-disrupted cells.
Total cell, cytoplasmic and nuclear extracts from Cos-7 cells transfected with non-tagged BRCA1 were analysed in immunoblots probed with three dierent BRCA1 antibodies (I-20, B112 and C-20; Figure 6c ). All three antibodies clearly recognized the 230 kDa overexpressed BRCA1 protein in the total cell lysates and the majority of the overexpressed protein was recovered in the nuclear fractions. The I-20 antibody also recognized an abundant, predominantly cytoplasmic protein slightly smaller than BRCA1. This species is probably not BRCA1 since the protein was not detected with either the B112 or the C-20 antibody.
The subcellular localization data and relative expression levels of all BRCA1 proteins described in this report are summarized in Figure 7 . The amount of protein detected in immunoblots correlated well with the level of immuno¯uorescent signal and number of positive cells observed in situ. These data indicate that cytoplasmically located BRCA1 proteins to accumulate to higher levels than those targeted to the nucleus. Full length BRCA1 and BRCA1 (1 ± 1667) exhibited the lowest levels of protein expression. It is likely that the low levels of these proteins relative to BRCA1-D11b and other partial BRCA1 proteins was a manifestation of toxicity.
Discussion
The BRCA1 gene and its protein product have been the subjects of intensive investigation because of its important role in hereditary and putative role in sporadic human breast and ovarian cancers (Chen et al., 1995) . Of particular interest has been the expression pattern of BRCA1 in both normal and malignant breast tissues as well as in other tissues in the body and the subcellular localization of the protein. Such studies have been conducted in hopes of gaining some insight into the function of this important molecule. There has been some controversy however, regarding the size and subcellular localization of the protein. Some investigations have reported that BRCA1 is a 220 kDa protein (Chen et al., 1995 (Chen et al., , 1996 Scully et al., 1990 ) (our estimate is 230 kDa) which is targeted to the nucleus of normal breast cells but which is found in the cytoplasm of malignant breast cells. Other studies have indicated that the protein is a 180 ± 190 kDa secreted tumor suppressing molecule (Jensen et al., 1996a,b) . This report attempts to address these issues and presents data regarding the size, subcellular localization, expression pattern and biological activity of two BRCA1 gene products, the full length product and a variant that is widely expressed in human cells.
Given the uncertainty inherent in the utilization of BRCA1 antibodies, we elected to analyse BRCA1 protein sorting with expression vectors that produce proteins tagged with short epitopes recognized by well de®ned monoclonal antibodies. Epitope tags have proven reliable for the analysis of nuclear targeting since a given NLS can function at a variety of positions in a protein (Roberts et al., 1987) , however insertion of tags could potentially disrupt normal protein targeting. To circumvent this potential problem we characterized BRCA1 subcellular localization with both N-terminal and C-terminal tags as well as non-tagged proteins.
The deletion analysis shown in Figure 5 demonstrates that a strong NLS is encoded in exon 11b between amino acid positions 263 ± 570 based on data demonstrating that the myc-tagged BRCA1 proteins including this sequence (2 ± 570, 89 ± 679, 223 ± 1365, 263 ± 1365) were targeted to the nucleus with very high eciency. These partial proteins were uniformly distributed throughout the nucleus with the exception of the nucleolus where they appeared to be excluded. We believe that the NLS in exon 11b is also capable of directing the full length BRCA1 protein to the nucleus as shown by the immuno¯uorescent images in Figure  4a ± j and in cell fractionation experiments (Figure 6c ).
Cells transfected with full length BRCA1 plasmids exhibited several signs of physiological stress that were not obvious in the cultures expressing the D11b variant or various deletion constructs. The toxicity associated with overexpression of the full length protein was manifest in weak nuclear signals, low levels of protein production that could not be increased by selection for plasmid born drug resistance markers, nuclear and cell fragmentation, loss of cell adherence and increased cell killing. The mechanisms of BRCA1 induced cell killing as well as the reasons that the process is associated with the accumulation of high levels of BRCA1 in the cytoplasm are not yet clear. Excessive nuclear BRCA1 protein could activate a cell death program, as a result of speci®c gene regulation or generalized transcriptional interference (Gill and Ptashne, 1988) , that in the early stages results in cessation of nuclear import or nuclear membrane leakage while allowing synthesis of BRCA1 in the cytoplasm to continue.
In this report we also describe a BRCA1 protein of 760 amino acids in which residues 263 to 1364 have been deleted by alternative splicing of exon 11b. The BRCA1-D11b variant migrates above its predicted size (110 vs 85 kDa), which is also the case with the full length protein. The sequence of the BRCA1-D11b protein was deduced from a PCR ampli®cation product. To demonstrate that this product is transcribed at physiologically signi®cant levels, ribonuclease protection assays and RT ± PCR were used to characterize BRCA1 transcripts in vivo. The results indicate that BRCA1-D11b mRNA is expressed at similar levels as transcripts containing exon 11 in a wide variety of human tissues, tumors and cell lines suggesting that like BRCA1, the D11b variant has a general role in cell proliferation and dierentiation. In the human, Northern blot analysis with probes from the BRCA1 C-terminal exons have detected two transcripts of 8 and 4.6 kb (Gudas et al., 1995 (Gudas et al., , 1996 . The 8 kb transcript appears to encode the full length protein since it also hybridizes with probes for exon 11. The smaller transcript which was not detected with an exon 11b probe is close to the predicted size of a BRCA1 transcript missing exon 11b (Gudas et al., 1995 (Gudas et al., , 1996 (8.0 ± 3.3=4.7) and is therefore a strong candidate for the BRCA1-D11b message. RT ± PCR analyses have shown that elimination of exon 11b by dierential splicing also occurs in the mouse (Hakem et al., 1996) . This evolutionary conservation of the BRCA1-D11b transcript is further evidence that this message may encode a protein of physiologic importance.
The BRCA1-D11b protein appears to be functionally distinct from full length BRCA1 in several respects. First, as a consequence of splice elimination of the NLS encoded in exon 11b, the protein cannot autonomously translocate to the nucleus. Results obtained with exogenous proteins clearly indicate that BRCA1-D11b is cytoplasmic, supporting this model. Secondly, BRCA1-D11b does not exhibit the cell toxicity apparent with overexpression of the full length protein in transiently transfected cells. While this toxicity appears to require a functional NLS, a protein encoded by exon 11 (223 ± 1365) was not toxic indicating other sequences outside this exon are probably necessary. The fact that BRCA1-D11b message was dierentially reduced or absent in breast and ovarian tumor cell lines relative to exon 11b and transcripts with and without exons 9,10 constitutes a third indication that the D11b variant may be functionally distinct. The most direct path to determining the function of BRCA1-D11b would be the characterization mutations that destroy the exon 11a splice donor without aecting the synthesis of the full length 1863 amino acid protein. While mutations that disrupt a number of BRCA1 splice junctions have been described (Collins, 1996) (and references therein), to our knowledge none would speci®cally aect BRCA1-D11b.
The highest levels of full length BRCA1 and BRCA1-D11b message that we have detected occurred in HBL100 cells and even in these cells the transcripts are classi®ed as rare. Transcript prevalence measurements presented here allowed us to estimate the maximum accumulation rate of BRCA1 proteins usually generally accepted parameters for protein synthesis in growing cells (Bag, 1991; Slobin, 1991; Godefroy-Colburn and Thach, 1981; Bergmann and Lodish, 1979) . Assuming that 50% of mRNAs are loaded onto polysomes in growing cells, that on average 50 ribosomes are loaded per polysomal message and that the rate of polypeptide chain elongation is about 400 amino acids per min, in the 24 h period before cell division an HBL100 cell has the capacity to produce about 240 000 molecules (3160.56506400660624/1863) of BRCA1 and about 150 000 molecules of BRCA1-D11b. The amount of protein present in growing cells would reach a maximum of twice these values, assuming that the BRCA1 proteins are in®nitely stable and that growing HBL100 cells double in a 24 h period. Since RT ± PCR analysis suggest that the concentration of BRCA1 transcripts in most cells is at least ®ve to tenfold lower than levels observed in HBL100 cells, the typical abundance of full length BRCA1 protein is probably in the range of 24 000 ± 48 000 molecules per G 1 -cell. These estimates are important because they serve as a baseline for interpreting the physiological eects observed in BRCA1 transfection experiments. The CMV promoter vectors that we have used produce mRNA levels (Boshart et al., 1985; Akrigg et al., 1985) that greatly exceed the maximum prevalence of endogenous BRCA1 transcripts in non-tranfected cells. Thus, whether or not full length BRCA1 promotes cell killing in natural situations remains to be demonstrated. Nonetheless, our results raise interesting possibilities for the mechanism of BRCA1 tumor suppression in the breast and ovary that may be tested directly.
It is informative to compare the estimated BRCA1 protein abundance to the sensitivity of the immunological techniques that have been employed to characterized BRCA1 proteins. Under optimum conditions, manufacturers cite 1 pg for the sensitivity of HRPchemiluminescent detection with immunoblots, however, in our hands 100 pg has proven more realistic. At the maximum accumulation rate, immunoblots of total proteins in a sample representing 3610 5 cells should contain 2.6 to 26 ng of BRCA1 protein. These amounts are at least 1 ± 2 orders of magnitude greater than the minimum detectable level and should generate a substantial signal with an antibody of Kd approximately equal to 10
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. In fact, we have not consistently oberved a convincing 230 kDa signal representing full length BRCA1 using the available commerical antibodies in immunoblots of total cell proteins. The major bands observed in immunoblots of endogenous proteins probably represent non-speci®c reactions (e.g. EGFR, Her2 and the 220 kDa protein recognized by I-20) that are more abundant than BRCA1. While the speci®city of several commercial antibodies and our B112 was clearly sucient to identify overexpressed protein (Figure 6 ), the diculty detecting endogenous BRCA1 proteins probably indicates that their abundance is limited post-translationally.
Our analysis of BRCA1 and BRCA1-D11b subcellular localization provided no evidence that these proteins are secreted as intact or nearly intact molecules. The cytoplasmic images that we have observed for these proteins are not consistent with secretion through the ER-Golgi. We believe that the overexpressed 190 kDa protein characterized in MDA-MB-468 cells by Jensen et al. (1996a) is the EGFR and not BRCA1 (1 ± 1863) for three reasons. First, we have shown that the C-20 antibody crossreacts with EGFR (Wilson et al., 1996) . Second, the MDA-MB-468 protein detected with comigrates with EGFR and is at least 40 kDa smaller than the apparent molecular weight observed for full-length BRCA1 in SDS ± PAGE. Third, it is well known that EGFR is overexpressed at the level of about 2 million molecules per MDA-MB-468 cell (Filmus et al., 1985) which were the cells used in the analysis (Jensen et al., 1996a) . The discordance between the observed 190 kDa protein level and BRCA1 mRNA prevalence was a critical factor in leading us to question the authenticity of the 190 kDa band recognized by the C-20 antibody as BRCA1 in MDA-MB-468 and A431 cells. In our experience overexpressed tyrosine kinase receptors are frequently recovered in conditioned media as a result of cell damage. This problem could be exacerbated in cultures transfected with full length BRCA1 plasmids as a consequence of cell death associated with overexpression. The data presented in this report does not permit us to categorically exclude the existence of a secreted BRCA1 protein variant derived by an as yet uncharacterized pattern of alternative splicing or protein processing. Moreover, while genes encoding proteins targeted for both secretion and nuclear import are highly unusual, they are not unknown. Alternative translation initiation generates forms of ®broblast growth factors bFGF and FGF-3 with N-terminal extensions that include an NLS which overrides other subcellular localization signals (Kiefer et al., 1994; Fernig and Gallagher, 1994) . FGF-3 has been shown to contain an N-terminal export signal, while bFGF does not. Interestingly, release of bFGF has been proposed to occur by transient cell wounding or exocytosis.
Whether or not full length BRCA1 is exclusively localized in the nucleus of all cells has been a controversy that is distinct from the debate regarding BRCA1 secretion (Chen et al., 1996; Scully et al., 1996) . Most groups agree that full length BRCA1 is nuclear in many cell types, however, the signi®cance of cytoplasmic localization has been contested. Our results suggest that the BRCA1-D11b protein may have been confused for cytoplasmic full-length BRCA1 in instances where an antibody speci®c for exon 11b antibody was not used to characterize endogenous proteins in situ. It is not clear whether or not the cytoplasmic localization we describe here in cells transfected with full length BRCA1 plasmids represents the same phenomenon described by Chen et al. (1995 Chen et al. ( , 1996 . It is important to note that unlike the cell line data presented by this group, the vast number of actual tumors examined exhibited both cytoplasmic and nuclear staining, indicating that the malignant process is not simply a matter of relocating the BRCA1 protein. Our data suggests that at relatively low levels of expression, cytoplasmically localized protein is not necessarily associated with cell death (Figure 4i ± l) . It is therefore possible that BRCA1 nuclear localization is a regulated process during normal cell growth or in response to physiological stimuli. Undoubtedly, further studies will be required to fully understand the role of BRCA1 proteins in normal and malignant processes.
Materials and methods
Construction of CMV expression plasmids
To construct pcDNA3-myc(N), a CMV promoter vector that introduces two myc epitopes at the N-terminus of expressed proteins, the sequence shown below was inserted into the BamHI/XbaI sites of pcDNA3 (Invitrogen).
This sequence contains a 30 nt 5' untranslated region (UTR) derived from the human GAPDH mRNA, a translation start, two copies of a c-myc epitope tag (Pati, 1992; Evan et al., 1985) indicated in bold, a short sequence derived from SpP3A2 (Calzone et al., 1991) and a XhoI, EcoRI, NotI multiple cloning site. The underlined regions show the primers used to PCR amplify the myc-tag insert from an SpP3A2 cDNA construct containing two myc-tags inserted at the EspI site (C Wilson; unpublished). pcDNA3 ± 5'UTR was identical to pcDNA3-myc(N) except that the SpP3A2 derived myc tags were absent. This construct was used to express proteins without myc epitopes. The CMV promoter vector pCEP4-myc(C) was generated to add the myc-tags to the C-terminus of expressed proteins. The sequence shown below was inserted into the KpnI/BamHI sites of pCEP4 (Invitrogen). The BRCA1 cDNA clones described in this report originated with PCR ampli®cation products obtained from breast tumor and colonic epithelial cDNA libraries or from Advantage PCR template (testes) (Clontech) using primers derived from the GenBank BRCA1 sequence (#U14680) and the appropriate restriction site overhangs. In most cases positions 1,2 of BRCA1 were changed from DL to LE and a leucine was added to the C-terminus to facilitate cloning. The Expand PCR system (Boehringer Mannheim), Deep Vent Polymerase (New England Biolabs) and the Advantage PCR Kit (Clontech) were used for ampli®cation. All clones generated by PCR were fully sequenced after screening with a coupled transcription/translation system (Promega) to identify nonsense mutants. The sequence of constructs encoding amino acids 1 ± 222, 1 ± 262, 1 ± 355, 1 ± 570, 89 ± 679 were identical to the GenBank U14680 sequence. Given the high degree of BRCA1 sequence polymorphism (Ithier, 1996) and the error rate of PCR we were unable to isolate a full length BRCA1 cDNA that matched the GenBank sequence exactly. For this reason two BRCA1 expression clones were utilized for cell transfections. The N-terminal myc-tagged, and non-tagged overexpressed BRCA1 were derived from a full length cDNA insert ampli®ed from testes cDNA and contained the following changes from the published sequence: Q418 deleted, D201 to A, S1173 to N and E1527 to G. The C-terminal myc-tag BRCA1 (1 ± 1863) was assembled from three overlapping cDNA inserts ampli®ed from breast cell-line and colon cDNA libraries and contained dierent changes (N417 to D, R613 to K, E1038 to G, K1183 to R, A1453 deleted, S1613 to P, Q1826 to R). BRCA1 (1 ± 1667) contained two substitutions: D435 to G and I845 to M. The dierences were N417 to D, R613 to K, E1038 to G, K1183 to R in BRCA1 (223 ± 1365); P871 to L, K912 to R, E1038 to G, K1138 to R in BRCA1 (263 ± 1365); A1453 deleted L1565 to Q, S1613 to G, Q1826 to R in BRCA1 (1366 ± 1863) and H239 to R, A253 to V, S1426 to P, A1453 deleted S1613 to G in BRCA1-D11b. The dierences indicated in bold were observed in two or more independently isolated cDNA inserts and are interpreted to be natural polymorphisms unrelated to PCR ampli®cation. The EGFR expression clones were generated by PCR using a human EGFR cDNA clone as a template.
Cell culture and transfections
The 293-EBNA human kidney cell line (Invitrogen) and simian Cos-7 kidney cells were cultured in DMEM (Dulbecco's Modi®ed Eagle's Media) with glutamine (Gibco) supplemented with 10% fetal bovine serum (FBS), 100 U ml 71 penicillin (P) and 100 U ml 71 streptomycin (S). The MDA-MB-468 tumor cell line was cultured in RPMI 1640 with FBS/P/S. All cells were grown at 378C in humidi®ed 8% CO 2 atmosphere. Plasmids were transfected using Lipofectamine Reagent (Gibco) as described in the manufacturer's protocol. Cells were grown to approximately 70% con¯uency in 6-well tissue culture plates and incubated with serum free DMEM containing 10 ml of liposomes complexes with 2 ± 4 mg of DNA. The transfection mix was removed after 5 h. DMEM containing FBS/P/S was added and the cells were grown for an additional 36 ± 40 h. Small scale transfections (0.5 ± 2 mg DNA) with approximately 1610 5 cells seeded in 2-well chambered coverslips (Nunc) were used for the immuno¯uoresence assays.
Cell fractionation and lysate preparation
Large scale transfected cultures were released from tissue culture¯asks by trypsin digestion. The cells were washed with excess culture medium and PBS to remove trypsin and resuspended in 10 ± 206the cell pellet volume of lysis buer (lysis buer is 5 mM KCl, 1 mM MgCl 2 , 20 mM Hepes (pH 7.5). After incubation for 30 min on ice and addition of 1/1000 dilution of Aprotinin and Pefabloc (Boehringer), the cells were homogenized with a tight ®tting dounce. An equal volume of lysis buer containing 0.2% NP-40, 0.1% DOC, 2 mM dithiothretol, 20% glycerol and protease inhibitors was added to complete lysis. Nuclei and insoluble cytoplasmic proteins were collected by centrifugation at about 3000 g. The nuclear pellet was washed once with detergent containing lysis buer. A small scale cell fractionation protocol was also used to prepare full length myc tagged BRCA1 protein from 293-EBNA cells where it was expressed at low levels and non-epitope tagged full length BRCA1 from Cos-7 cells. Transfected or nontransfected cells grown to about 90% con¯uency in 6-well or 90 mM tissue culture plates were washed with PBS and lysed in 500 ml of low salt lysis buer (50 mM NaCl, 50 mM (Tris pH 7.0), 5 mM MgCl 2 and 1% Triton X-100) to obtain the cytoplasmic fraction. The nuclear and insoluble material was pelleted at 10 000 g and washed in low salt lysis buer. The nuclear proteins were released from the chromatin by the addition of lysis buer adjusted to 300 mM NaCl and brief sonication or by direct lysis in SDS sample buer.
Immunoblots
Protein samples were boiled in SDS sample buer containing b-mercaptoethanol, subjected to SDS ± PAGE on 6, 8 or 10% acrylamide gels and transferred to PVDF membranes. All buers, gels and membranes were purchased from Novex. After transfer, the membranes were blocked for several h with TBS-T containing 9% nonfat dry milk (TBS-T is saline buered with 25 mM TrisHCl (pH 7.4) containing 0.1% Tween-20). The myc-tagged proteins were detected on Western blots using an a-myc (Ab-1) monoclonal antibody (Oncogene Science) diluted 1 : 50 in TBS-T plus 1% milk. Transfected BRCA1 proteins GAT CCG CCA GCCGAGCCACATCGCTCAGACAC-CAT GAT CGC AAA TGT GAA TATTGC TCAGGAA-CAAAAGCTTATTTCTGAAGAAGACTTGGCTCAG-GAACAAAAGCTTATTTCTGAAGAAGACTTGG CT-CAGCAGAGTGGCGGAGGACTCGAGGAATTCGCG-GCCGCTCTAG GTACCGCCAGCCGAGCCACATCGCTCAGACACC-ATG CTC GAG GAA TTCGCGGCCGCAATCGCAAA-TGTGAATATTGCTCAGGAACAAAAGCTTATTTC-TGAAGAAGACTTGGCTCAGGAACAAAAGCTTAT-TTCTGAAGAAGACTTGGCTCAGCAGAGTGGCGG-AGGATAGTAGGTCGACGGATC were also detected with two dierent anti-peptide polyclonal antibodies: C-20 raised against BRCA1 amino acids 1843 ± 1862 (Santa Cruz) and I-20 raised against residues 1823 ± 1842 (Santa Cruz) diluted 1 : 300 and a rabbit antisera raised against a bacterially produced GST fusion protein containing amino acids 2 ± 355 of BRCA1 diluted 1 : 1000. After several washes, the blots were incubated with a 1 : 5000 dilution of goat-anti-rabbit or mouse-HRP (Santa Cruz). Antibody complexes were detected with ECL chemiluminescent system (Amersham).
Immuno¯uorescence
Transfected and untransfected control 293-EBNA and Cos-7 cells grown on chambered coverslips were washed with PBS, ®xed in ice cold 100% methanol for 5 min followed by 50% acetone/50% methanol for 1 min and allowed to air dry. The cells were washed 36 in PBS and blocked in buer P1+ (PBS with 10% normal goat serum, 0.1% BSA and 1% Triton X-100) for several h. The anti-myc-1 antibody, diluted 1 : 25 in buer P1+, was incubated with the cells overnight at 48C. After 3 ± 4 washes with buer P1 (PBS containing 0.1% BSA and 0.05% Triton X-100), the cells were incubated for 2 h with a 1 : 200 dilution of the FITC-conjugated secondary antibody (goat anti-mouse IgG (Southern Biotech)). Nuclei were stained brie¯y with propidium iodide. Two color¯uorescence was visualized and digitally captured with a 1006 oil immersion lens on a ACAS Ultima (Meridian) confocal microscope. Images of FITC stained cells were also obtained using a Nikon Microphot-FXA microscope equipped with a color video printer. Digital images were assembled, cropped and labeled in Adobe Photoshop and printed on a Tektronix Phase 440.
RNA analysis
To isolate total RNA, cells and tissues were lysed in guanidium isothiocyanate and RNA was pelleted through CsTFA using reagents and a protocol provided by Pharmacia. The RNA probe used to measure BRCA1 message levels was generated using a 368 bp PCR ampli®cation product derived from BRCA1-D11b. The sense primer (GAACATCATCAACCCAGTAAT) corresponded to nucleotides 828 ± 848 of the full-length sequence, and the reverse primer (ggatccaatacgactcactatagggaggGCTTTTTCTGATGTGCTTTGTTC) contained a T 7 promoter (lowercase) and nucleotides 4456 ± 4478 of the antisense strand. The PCR product was gel-puri®ed, eluted and concentrated by ethanol precipitation. A T 7 MAXIscript kit (Ambion) was used for the RNA transcription reactions which contained approximately 1 mg of template and 50 mCi 32 P-UTP (800 Ci/mM). After synthesis, DNase I was added to digest the template and the transcripts were gel puri®ed. The GAPDH probe was synthesized in the same manner using the template provided by the manufacturer (Ambion). RNA probe titrations were performed essentially as described by Lee and Kostlow (1987) using components of the Ambion RPA II system. A series of reactions containing 20 ± 100 mg of total HBL100 RNA or 20 mg total yeast RNA were incubated overnight at 458C with 1.5610 4 c.p.m. of RNA probe. The samples were digested with a 1/100 dilution of RNase A and RNase T1 for 45 min at 378C and ethanol precipitated in the presence of RNase inactivators. The protected fragments were resolved on a 6% denaturing polyacrylamide gel together with 32 P end-labeled DNA markers (Boehringer Mannheim Marker XI). The dried gel was exposed and the bands were quantitated on a Phosphoimager (Molecular Dynamics) equipped with ImageQuant software.
A Biomek 2000 (Beckman) was used to assemble RT ± PCR reactions. Four 50 ml reactions were assembled for each RNA sample containing 250, 50, 10 or 2 ng of template, 16EZ buer (Perkin Elmer), 0.5 mM dNTPs, 3 mM Mn(OAc) 2 , 5% sucrose, 0.0001% phenol red, 20 pmol each forward and reverse primer, and 2 ml of rTth polymerase (Perkin Elmer). After a reverse transcription cycle (30 min/ 608C) the reactions underwent 40 two-step ampli®cation cycles (15 s/948C-30 s/608C) and one 7 min/608C extension. The RT ± PCR primers are described in Table 1 . The products were analysed on 2% agarose gels containing 5 mg/ml ethidium bromide and the u.v.-¯uorescent images were digitally captured using an EagleEye (Stratagene).
